The payroll report missed badly, as the headline "job creation" number gained only 38k in May 2016. That was the lowest monthly gain of the entire "recovery." Last month's figure, which had already ...
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) ...
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II Variation Application ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) for the treatment of adult patients with HER2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results